Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Get Free Report) COO Eben Tessari sold 17,500 shares of the firm’s stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $26.91, for a total value of $470,925.00. Following the completion of the sale, the chief operating officer now owns 119,911 shares in the company, valued at $3,226,805.01. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.
Kiniksa Pharmaceuticals Stock Performance
KNSA opened at $26.74 on Friday. The stock’s fifty day moving average is $23.45 and its 200-day moving average is $20.72. Kiniksa Pharmaceuticals, Ltd. has a one year low of $14.12 and a one year high of $27.92. The company has a market capitalization of $1.90 billion, a PE ratio of 243.09 and a beta of 0.38.
Kiniksa Pharmaceuticals (NASDAQ:KNSA – Get Free Report) last issued its quarterly earnings results on Tuesday, July 23rd. The company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.03. The company had revenue of $108.30 million during the quarter, compared to the consensus estimate of $90.60 million. Kiniksa Pharmaceuticals had a negative net margin of 3.10% and a negative return on equity of 7.79%. Kiniksa Pharmaceuticals’s revenue was up 51.5% on a year-over-year basis. During the same period in the prior year, the company earned ($0.02) EPS. On average, equities research analysts forecast that Kiniksa Pharmaceuticals, Ltd. will post -0.05 EPS for the current fiscal year.
Analysts Set New Price Targets
Read Our Latest Research Report on KNSA
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in the business. Lazard Asset Management LLC acquired a new stake in shares of Kiniksa Pharmaceuticals during the 1st quarter valued at $71,000. Ashton Thomas Private Wealth LLC acquired a new stake in shares of Kiniksa Pharmaceuticals during the second quarter worth $100,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Kiniksa Pharmaceuticals by 88.1% during the first quarter. China Universal Asset Management Co. Ltd. now owns 7,708 shares of the company’s stock valued at $152,000 after purchasing an additional 3,611 shares during the last quarter. Lynx1 Capital Management LP acquired a new position in shares of Kiniksa Pharmaceuticals in the 2nd quarter valued at $177,000. Finally, Arizona State Retirement System purchased a new position in Kiniksa Pharmaceuticals in the 2nd quarter worth about $209,000. Institutional investors and hedge funds own 53.95% of the company’s stock.
About Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.
See Also
- Five stocks we like better than Kiniksa Pharmaceuticals
- Do ETFs Pay Dividends? What You Need to Know
- The Solar Stock Battle: Is Daqo or JinkoSolar Your Next Big Win?
- Comparing and Trading High PE Ratio Stocks
- Are These Chinese Stocks a Buy? Michael Burry’s Top Picks Say Yes
- Investing in Construction Stocks
- Five Below Stock Faces Challenges Despite Strong Revenue Growth
Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.